Nothing
tests/testthat/_snaps/ttet01.md
In chevron: Standard TLGs for Clinical Trials Reporting
ttet01 works as expected
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Adverse Event 0 0 0
Death 5 11 7
Disease Progression 2 1 1
Last Tumor Assessment 0 0 0
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Unstratified Analysis
p-value (log-rank) 0.0973 0.9111
Hazard Ratio 2.18 1.06
95% CI (0.85, 5.60) (0.38, 2.94)
180 MONTHS
Patients remaining at risk NE NE NE
Event Free Rate (%) NE NE NE
95% CI NE NE NE
Difference in Event Free Rate NE NE
95% CI NE NE
p-value (Z-test) NE NE
360 MONTHS
Patients remaining at risk NE NE NE
Event Free Rate (%) NE NE NE
95% CI NE NE NE
Difference in Event Free Rate NE NE
95% CI NE NE
p-value (Z-test) NE NE
————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————
ttet01 works as expected for stratified and unstratified analysis
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Unstratified Analysis
p-value (log-rank) 0.0973 0.9111
Hazard Ratio 2.18 1.06
95% CI (0.85, 5.60) (0.38, 2.94)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Death 5 11 7
Disease Progression 2 1 1
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.8372
Hazard Ratio 2.11 0.86
95% CI (0.75, 5.96) (0.21, 3.49)
Unstratified Analysis
p-value (log-rank) 0.0973 0.9111
Hazard Ratio 2.18 1.06
95% CI (0.85, 5.60) (0.38, 2.94)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
ttet01 works as expected for stratified analysis only
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.8372
Hazard Ratio 2.11 0.86
95% CI (0.75, 5.96) (0.21, 3.49)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Death 5 11 7
Disease Progression 2 1 1
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.8372
Hazard Ratio 2.11 0.86
95% CI (0.75, 5.96) (0.21, 3.49)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
ttet01 works if change reference group
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Unstratified Analysis
p-value (log-rank) 0.0973 0.0795
Hazard Ratio 0.46 0.45
95% CI (0.18, 1.18) (0.18, 1.12)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate 20.00 20.00
95% CI (-13.74, 53.74) (-13.74, 53.74)
p-value (Z-test) 0.2453 0.2453
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Death 5 11 7
Disease Progression 2 1 1
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.1587
Hazard Ratio 0.47 0.40
95% CI (0.17, 1.34) (0.11, 1.49)
Unstratified Analysis
p-value (log-rank) 0.0973 0.0795
Hazard Ratio 0.46 0.45
95% CI (0.18, 1.18) (0.18, 1.12)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate 20.00 20.00
95% CI (-13.74, 53.74) (-13.74, 53.74)
p-value (Z-test) 0.2453 0.2453
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Try the chevron package in your browser
Any scripts or data that you put into this service are public.
chevron documentation built on June 20, 2025, 5:08 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
ttet01 works as expected
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Adverse Event 0 0 0
Death 5 11 7
Disease Progression 2 1 1
Last Tumor Assessment 0 0 0
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Unstratified Analysis
p-value (log-rank) 0.0973 0.9111
Hazard Ratio 2.18 1.06
95% CI (0.85, 5.60) (0.38, 2.94)
180 MONTHS
Patients remaining at risk NE NE NE
Event Free Rate (%) NE NE NE
95% CI NE NE NE
Difference in Event Free Rate NE NE
95% CI NE NE
p-value (Z-test) NE NE
360 MONTHS
Patients remaining at risk NE NE NE
Event Free Rate (%) NE NE NE
95% CI NE NE NE
Difference in Event Free Rate NE NE
95% CI NE NE
p-value (Z-test) NE NE
————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————
ttet01 works as expected for stratified and unstratified analysis
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Unstratified Analysis
p-value (log-rank) 0.0973 0.9111
Hazard Ratio 2.18 1.06
95% CI (0.85, 5.60) (0.38, 2.94)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Death 5 11 7
Disease Progression 2 1 1
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.8372
Hazard Ratio 2.11 0.86
95% CI (0.75, 5.96) (0.21, 3.49)
Unstratified Analysis
p-value (log-rank) 0.0973 0.9111
Hazard Ratio 2.18 1.06
95% CI (0.85, 5.60) (0.38, 2.94)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
ttet01 works as expected for stratified analysis only
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.8372
Hazard Ratio 2.11 0.86
95% CI (0.75, 5.96) (0.21, 3.49)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Death 5 11 7
Disease Progression 2 1 1
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.8372
Hazard Ratio 2.11 0.86
95% CI (0.75, 5.96) (0.21, 3.49)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate -20.00 0.00
95% CI (-53.74, 13.74) (-31.65, 31.65)
p-value (Z-test) 0.2453 1.0000
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
ttet01 works if change reference group
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Unstratified Analysis
p-value (log-rank) 0.0973 0.0795
Hazard Ratio 0.46 0.45
95% CI (0.18, 1.18) (0.18, 1.12)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate 20.00 20.00
95% CI (-13.74, 53.74) (-13.74, 53.74)
p-value (Z-test) 0.2453 0.2453
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Code
cat(export_as_txt(res, lpp = 100))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————
Patients with event (%) 7 (46.7%) 12 (80%) 8 (53.3%)
Earliest contributing event
Death 5 11 7
Disease Progression 2 1 1
Patients without event (%) 8 (53.3%) 3 (20%) 7 (46.7%)
Time to Event (MONTHS)
Median 8.6 6.2 8.4
95% CI (2.6, NE) (2.2, 7.6) (3.8, NE)
25% and 75%-ile 3.8, NE 4.7, 8.4 5.8, NE
Range 1.2 to 9.5 {1} 0.9 to 9.1 0.9 to 9.5 {1}
Stratified Analysis
p-value (log-rank) 0.1505 0.1587
Hazard Ratio 0.47 0.40
95% CI (0.17, 1.34) (0.11, 1.49)
Unstratified Analysis
p-value (log-rank) 0.0973 0.0795
Hazard Ratio 0.46 0.45
95% CI (0.18, 1.18) (0.18, 1.12)
6 MONTHS
Patients remaining at risk 11 8 11
Event Free Rate (%) 73.33 53.33 73.33
95% CI (43.62, 89.05) (26.32, 74.38) (43.62, 89.05)
Difference in Event Free Rate 20.00 20.00
95% CI (-13.74, 53.74) (-13.74, 53.74)
p-value (Z-test) 0.2453 0.2453
————————————————————————————————————————————————————————————————————————————————————
{1} - Censored observation: range maximum
————————————————————————————————————————————————————————————————————————————————————
Try the chevron package in your browser
Any scripts or data that you put into this service are public.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.